The Efficacy and Safety of Hirudin Plus Aspirin Versus Warfarin in the Secondary Prevention of Cardioembolic Stroke Due to Nonvalvular Atrial Fibrillation: a Prospective Cohort Study

To investigate the efficacy and safety of hirudin plus aspirin therapy compared with warfarin in the secondary prevention of cardioembolic stroke due to nonvalvular atrial fibrillation.

Start Date01 Jun 2014

Sponsor / Collaborator

Xijing Hospital

[+7]

NCT00913133

/ CompletedPhase 4

Multi-Center Trial of Desirudin for the Prophylaxis of Thrombosis: an Alternative to Heparin-Based Anticoagulation (DESIR-ABLE)

The objective of this trial is to demonstrate the clinical utility of fixed-dose SC Desirudin for the prophylaxis of thrombosis as an alternative to heparin-based anticoagulation.

Start Date01 Mar 2010

Sponsor / Collaborator

Canyon Pharmaceuticals, Inc.

NL-OMON35683

/ CompletedPhase 2

Canyon-I-Pilot Trial a dose-ranging study of bolus-only Desirudin in patients undergoing PCI - CANYON-PCI pilot study

Start Date04 Sep 2009

Sponsor / Collaborator

Canyon Pharmaceuticals, Inc.

100 Clinical Results associated with Desirudin Recombinant

100 Translational Medicine associated with Desirudin Recombinant

100 Patents (Medical) associated with Desirudin Recombinant

120

Literatures (Medical) associated with Desirudin Recombinant

01 Nov 2022·British Journal of Pharmacology

A novel oncotherapy strategy: Direct thrombin inhibitors suppress progression, dissemination and spontaneous metastasis in non‐small cell lung cancer

Article

Author: Wu, Mengfang ; Wang, Qi ; Yu, Min ; Ma, Yixin ; Wang, Huijie ; Zhao, Bing ; Yu, Jinchao ; Wang, Tianfa ; Li, Yaran ; Hu, Zhihuang ; Mo, Wei ; Zhang, Yanling ; Li, Tianyu ; Chen, Di

Background and Purpose:

Cancer cachexia and cancer‐associated thrombosis are potentially fatal outcomes of advanced cancer. Nevertheless, thrombin expression in non‐small cell lung cancer (NSCLC) primary tumour tissues and the association between prognosis of NSCLC patients remain largely unknown.

Experimental Approach:

Clinical pathological analysis was performed to determine the relationship between thrombin and tumour progression. Effects of r‐hirudin and direct thrombin inhibitor peptide (DTIP) on cancer progression were evaluated. Western blotting, immunohistochemistry, and immunofluorescence were used to explore the inhibition mechanism of r‐hirudin and DTIP. The therapeutic effect of the combination of DTIP and chemotherapy was determined.

Key Results:

Thrombin expression in NSCLC tissues was closely related to clinicopathological features and the prognosis of patients. Thrombin deficiency inhibited tumour progression. The novel thrombin inhibitors, r‐hirudin and DTIP, inhibited cell invasion and metastasis in vitro. They inhibited tumour growth and metastasis in orthotopic lung cancer model, inhibited cell invasion, and prolonged survival after injection of tumour cells via the tail vein. They also inhibited angiogenesis and spontaneous metastases from subcutaneously inoculated tumours. The promotion by thrombin of invasion and metastasis was abolished in PAR‐1‐deficient NSCLC cells. r‐hirudin and DTIP inhibited tumour progression through the thrombin‐PAR‐1‐mediated RhoA and NF‐κB signalling cascades via inhibiting MMP9 and IL6 expression. DTIP potentiated chemotherapy‐induced growth and metastatic inhibition and inhibited chemotherapy‐induced resistance in mice.

Conclusions and Implications:

Thrombin makes a substantial contribution, together with PAR‐1, to NSCLC malignancy. The anti‐coagulants, r‐hirudin and DTIP, could be used in anti‐tumour therapy and a combination of DTIP and chemotherapy might improve therapeutic effects.

01 Oct 2022·Journal of endodontics

Microbiome Changes during Regenerative Endodontic Treatment Using Different Methods of Disinfection

Article

Author: Fouad, Ashraf F ; Torabinejad, Mahmoud ; Diogenes, Anibal R ; Hargreaves, Kenneth M

INTRODUCTION:

The purpose of this study was to characterize qualitatively and quantitatively the changes in the endodontic microbiome, in teeth with necrotic pulp, open apexes, and apical periodontitis, with 3 antimicrobial protocols, undertaken in a multicenter clinical trial.

METHODS:

Microbiological samples were collected from 116 regenerative endodontic teeth, and 97 qualified for inclusion. The teeth were randomly divided into 3 treatment groups: apexification (APEX), regeneration (REGEN), and revascularization (REVASC), all in 2 appointments. The group variables in the first appointment irrigants, and second appointment irrigants and medicaments were as follows: APEX: 5.25%-6% NaOCl, 5.25%-6% NaOCl + 17% EDTA and calcium hydroxide; REGEN: 1.25% NaOCl, 17% EDTA, and 0.1 mg/mL triple antibiotic paste (TAP); and REVASC 5.25% NaOCl, saline, and 1 g/mL TAP, respectively. Sampling was done upon access (S0), after irrigation in the first appointment (S1), and after using medication and irrigation in the second appointment (S2).

RESULTS:

Quantitative polymerase chain reaction analysis of the 16S ribosomal RNA gene showed significant reduction in bacterial load from S0 to S2 in all groups; however, the APEX and REVASC groups had significantly less residual DNA than the REGEN group (P = .0045). The relative abundance of Bacteroidetes, Fusobacteria, Spirochaetes, and Synergistetes were reduced with the treatment rendered. However, relative abundance of Firmicutes and Actinobacteria was not changed, and that of Proteobacteria increased. LEfSe analysis showed that reduction in bacterial taxa was more in REVASC than APEX, which in turn was more than in REGEN.

CONCLUSION:

Enhanced antimicrobial protocols lead to better reduction in quantitative and qualitative parameters of the endodontic microflora.

01 Aug 2021·International journal of clinical pharmacyQ4 · MEDICINE

Superior outcomes with Argatroban for heparin-induced thrombocytopenia: a Bayesian network meta-analysis

Q4 · MEDICINE

Review

Author: Maffulli, Nicola ; Hatam, Nima ; Tingart, Markus ; Colarossi, Giorgia ; Trivellas, Andromahi ; Schnöring, Heike ; Migliorini, Filippo

Abstract:

Background Argatroban, lepirudin, desirudin, bivalirudin, and danaparoid are commonly used to manage heparin-induced thrombocytopenia related complications. However, the most suitable drug for this condition still remains controversial. Aim of the review This Bayesian network meta-analysis study compared the most common anticoagulant drugs used in the management of heparin-induced thrombocytopenia. Method All clinical trials comparing two or more anticoagulant therapies for suspected or confirmed heparin-induced thrombocytopenia were considered for inclusion. Studies concerning the use of heparins or oral anticoagulants were not considered. Data concerning hospitalisation length, thromboembolic, major, and minor haemorrhagic events, and mortality rate were collected. The network analyses were made through the STATA routine for Bayesian hierarchical random-effects model analysis with standardised mean difference (SMD) and log odd ratio (LOR) effect measures. Results Data from a total of 4338 patients were analysed. The overall mean age was 62.31 ± 6.6 years old. Hospitalization length was considerably shorter in favour of the argatroban group (SMD: − 1.70). Argatroban evidenced the lowest rate of major (LOR: − 1.51) and minor (LOR: − 0.57) haemorrhagic events. Argatroban demonstrated the lowest rate of thromboembolic events (LOR: 0.62), and mortality rate (LOR: − 1.16). Conclusion Argatroban performed better overall for selected patients with HIT. Argatroban demonstrated the shortest hospitalization, and lowest rate of haemorrhages, thromboembolisms, and mortality compared to bivalirudin, lepirudin, desirudin, and danaparoid.

News (Medical) associated with Desirudin Recombinant

24 Nov 2016

·www.bioportfolio.com

Hybio Pharmaceutical Co., Ltd. 300199 Financial and Strategic SWOT Analysis Review Prices from USD $300

Summary Hybio Pharmaceutical Co., Ltd. Hybio is a biopharmaceutical company that develops polypeptide drugs. The company manufactures and develops peptide finished dosage products and peptide active pharmaceutical ingredients. Its finished dosage products include desmopressin for injection, terlipressin for injection, sodium ozagrel for injection, oxytocin for injection, omeprazole sodium for injection,and others. Hybio provides active pharmaceutical ingredients such as abarelix, calcitonin, copaxone, antide, desmopression, alarelin, bivalirudin, desirudin, elecatonin, fertirelin, ganadorelin, histrelin, leuprorelin, vapreotide and haxapeptide. The company conducts research and development to advance its products. Hybio is headquartered in Shenzhen, China. This comprehensive SWOT profile of Hybio Pharmaceutical Co., Ltd. provides you an indepth strategic analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. This company report forms part of GlobalData's Profile on Demand' service, covering over 50,000 of the world's leading companies. Once purchased, GlobalData's highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Hybio Pharmaceutical Co., Ltd. including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. excluding weekends. The profile contains critical company information including*, x000D x000D Business description A detailed description of the company's operations and business divisions.x000D Corporate strategy Analyst's summarization of the company's business strategy.x000D SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.x000D Company history Progression of key events associated with the company.x000D Major products and services A list of major products, services and brands of the company.x000D Key competitors A list of key competitors to the company.x000D Key employees A list of the key executives of the company.x000D Executive biographies A brief summary of the executives' employment history.x000D Key operational heads A list of personnel heading key departments/functions.x000D Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.x000D Key manufacturing facilities A list of key manufacturing facilities of the company.x000D Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.x000D Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.x000D x000D Note*: Some sections may be missing if data is unavailable for the company. Key benefits of buying this profile include,x000D x000D You get detailed information about the company and its operations to identify potential customers and suppliers.x000D The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.x000D x000D Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.x000D The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events. x000D x000D Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.x000D Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.x000D x000D Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.x000D Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.x000D x000D Gain key insights into the company for academic or business research.x000D Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Financial StatementAcquisition

100 Deals associated with Desirudin Recombinant

External Link

KEGG	Wiki	ATC	Drug Bank
-	Desirudin Recombinant	B01AE01	DB11095

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Venous Thrombosis	European Union	Canyon Pharmaceuticals, Inc.	09 Jul 1997
Venous Thrombosis	Iceland	Canyon Pharmaceuticals, Inc.	09 Jul 1997
Venous Thrombosis	Liechtenstein	Canyon Pharmaceuticals, Inc.	09 Jul 1997
Venous Thrombosis	Norway	Canyon Pharmaceuticals, Inc.	09 Jul 1997

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00913133 (DESIR-ABLE, CTgov)	Phase 4	Thrombosis	516	Desirudin	vmkgtihchx = pxzedbohzj baoglvikup (kcmpnswnyo, kwmlanfmlr - kaxjidwbhs) View more	-	03 Jan 2013
NCT00787332 (HIT, CTgov)	Phase 4	Leriche Syndrome \| Heparin-induced thrombocytopenia \| Heparin-induced thrombocytopenia and thrombosis	16	Argatroban+Desirudin (Desirudin)	ispsyslmdg = cofaxoyosa amvdhsboiu (ctvftatbck, vddolluqii - tesaqenvhk) View more	-	31 Dec 2012
NCT00787332 (HIT, CTgov)	Phase 4		16	Argatroban+Desirudin (Argatroban®)	ispsyslmdg = qfruynitaq amvdhsboiu (ctvftatbck, fhmmwdeknb - eiiwqbqrcz) View more	-	31 Dec 2012
NCT00329433 (CTgov)	Phase 2/3	Venous Thrombosis	120	Heparin	qvqbafumag = aozpvsmicj enkewhpree (iymcvubfqr, lpocknlcfy - aoxxvhxaxp) View more	-	13 Jun 2011

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis